Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thiothixene is a first-generation (typical) antipsychotic medication belonging to the thioxanthene class. It is primarily indicated for the treatment of schizophrenia, both acute and chronic, and may also be used in other psychiatric disorders such as bipolar disorder, mania, and behavioral disturbances[1][4][5]. Thiothixene acts mainly by antagonizing dopamine receptors (D1, D2, D3, D4), thereby reducing abnormal excitement in the brain and balancing dopamine levels to help regulate mood, behavior, and thoughts[1][2][3][6]. It also exhibits antagonistic activity at serotonergic (5-HT1 and 5-HT2), histaminergic (H1), alpha-adrenergic (alpha1/alpha2), and muscarinic cholinergic (M1/M2) receptors[3][6]. These actions contribute to its antipsychotic effects as well as its side effect profile. The drug is administered orally; it is rapidly absorbed with peak plasma concentrations within 1–3 hours after dosing. Thiothixene was originally developed by pharmaceutical companies such as Pfizer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thiothixene.